BioPorto A/S

Copenhagen Stock Exchange BIOPOR.CO

BioPorto A/S Gross Profit for the year ending December 31, 2023: USD 2.99 M

BioPorto A/S Gross Profit is USD 2.99 M for the year ending December 31, 2023, a 9.33% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • BioPorto A/S Gross Profit for the year ending December 31, 2022 was USD 2.73 M, a 18.86% change year over year.
  • BioPorto A/S Gross Profit for the year ending December 31, 2021 was USD 2.30 M, a 5.21% change year over year.
  • BioPorto A/S Gross Profit for the year ending December 31, 2020 was USD 2.18 M, a -15.77% change year over year.
  • BioPorto A/S Gross Profit for the year ending December 31, 2019 was USD 2.59 M, a -5.30% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Loading...
Copenhagen Stock Exchange: BIOPOR.CO

BioPorto A/S

CEO Mr. Peter Moerch Eriksen B.B.A., BBA
IPO Date Jan. 13, 2000
Location Denmark
Headquarters Tuborg Havnevej 15, st.
Employees 27
Sector Health Care
Industries
Description

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.

Similar companies

BAVA.CO

Bavarian Nordic A/S

USD 26.62

-0.36%

AMBU-B.CO

Ambu A/S

USD 18.73

1.26%

ZEAL.CO

Zealand Pharma A/S

USD 95.84

0.08%

StockViz Staff

January 15, 2025

Any question? Send us an email